30 completed, 7 terminated, 4 recruiting, 2 active not recruiting. 22 Phase 2, 13 Phase 3, 12 Phase 1, 1 Phase 4.
Follow Cytokinetics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HCMR Re-Imaging Study None - observational study - Hypertrophic Cardiomyopathy (HCM) | Recruiting | Christopher Kramer | 314 | 2026-07-27 | 2026-10-16 | |
| Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy Aficamten - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Recruiting | Oregon Health and Science University | 40 | 2026-05-05 | 2026-05-20 |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586 - Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Recruiting | Cytokinetics | 60 | 2025-02-06 | 2026-08-27 |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Omecamtiv Mecarbil (OM), Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 3 | Recruiting | Cytokinetics | 1800 | 2024-12-19 | 2026-10-13 |
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). Aficamten, Placebo - Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Active not recruiting | Cytokinetics | 65 | 2024-05-29 | 2026-08-18 |
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Aficamten, Placebo - Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active not recruiting | Cytokinetics | 500 | 2023-08-31 | 2026-09-22 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg) - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 | Completed | Cytokinetics | 175 | 2023-06-20 | 2026-06-09 |
| Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval Aficamten, Aficamten-matching Placebo, Moxifloxacin - Healthy Participants | Phase 1 | Completed | Cytokinetics | 44 | 2023-05-15 | 2023-12-19 |
| A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants CK-4021586, Placebo for CK-4021586 - Healthy Participants | Phase 1 | Completed | Cytokinetics | 102 | 2023-05-09 | 2025-05-01 |
| A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants CK-3828136, Placebo for CK-3828136 - Healthy Participants | Phase 1 | Terminated | Cytokinetics | 57 | 2022-12-06 | 2024-10-17 |
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) Reldesemtiv - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Cytokinetics | 71 | 2022-08-04 | 2024-08-13 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Phase 3 | Completed | Cytokinetics | 282 | 2022-02-01 | 2026-03-03 |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Reldesemtiv, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Cytokinetics | 489 | 2021-08-16 | 2024-12-05 |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM Aficamten (5 - 20 mg) - Symptomatic Hypertrophic Cardiomyopathy (HCM) | Phase 2 / Phase 3 | Enrolling by invitation | Cytokinetics | 900 | 2021-05-06 | 2026-10-13 |
| Safety, Tolerability and Pharmacokinetics Study of CK-3773274 CK-3773274, Placebo - Obstructive Hypertrophic Cardiomyopathy, Healthy Adult Subjects | Phase 1 | Completed | Corxel Pharmaceuticals | 28 | 2021-04-10 | 2025-01-24 |
| Omecamtiv Mecarbil Post-trial Access Study Omecamtiv mecarbil - Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 | Withdrawn | Cytokinetics | 2020-12-18 | 2021-07-30 | |
| Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274 - Hypertrophic Cardiomyopathy (HCM) | Phase 2 | Completed | Cytokinetics | 96 | 2020-01-10 | 2026-02-24 |
| Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults Omecamtiv Mecarbil (OM), Placebo, Moxifloxacin - QT Intervals Changes, QTc Intervals Changes | Phase 1 | Completed | Cytokinetics | 70 | 2019-11-14 | 2025-03-30 |
| Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure Omecamtiv Mecarbil, Placebo - Heart Failure With Reduced Ejection Fraction | Phase 3 | Completed | Cytokinetics | 276 | 2019-04-09 | 2023-03-07 |
| A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets - Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects | Phase 1 | Completed | Cytokinetics | 114 | 2018-12-04 | 2025-01-24 |
Showing 20 of 46. Sign in to see all of them.
Heart Failure (13) · Amyotrophic Lateral Sclerosis (9) · Cardiomyopathy, Hypertrophic (8) · Ventricular Dysfunction, Left (2) · Angina Pectoris (1) · Breast Neoplasms (1) · Dyspnea (1) · Hodgkin Disease (1) · Intermittent Claudication (1) · Lymphoma, Non-Hodgkin (1) · Mobility Limitation (1) · Muscular Atrophy, Spinal (1) · Myasthenia Gravis (1) · Myocardial Ischemia (1) · Peripheral Arterial Disease (1)
omecamtiv mecarbil (15) · CK-2017357 (8) · reldesemtiv (6) · Riluzole (3) · Moxifloxacin (2) · Capsules (1) · Infusions, Intravenous (1) · Metoprolol (1) · SB 743921 (1) · Standard of Care (1) · ispinesib (1)
United States (36) · Canada (17) · United Kingdom (17) · Italy (15) · Netherlands (15) · Spain (14) · Germany (13) · France (12) · Poland (9) · Australia (8) · Hungary (8) · Belgium (7) · Portugal (7) · China (6) · Denmark (6)
Jeremy Shefner, MD, PhD (3) · Andrew A Wolff, MD, FACC (2) · Alan Hirsch, MD (1) · Andrew Wolff, MD, FACC (1) · Christopher Kramer, MD (1) · Jeremy M Shefner, MD, PhD (1) · Jinsy Andrews, MD (1) · MD Cytokinetics (1) · Owen O'Connor, M.D./Ph.D. (1)
PMID 25951506, PMID 37254449, PMID 41347307, PMID 42624353, PMID 21856480, PMID 21856481, PMID 22591195, PMID 23952636, PMID 24872402, PMID 25453536, PMID 25665464, PMID 27012405, PMID 29402141, PMID 31081694, PMID 32035892, PMID 32969758, PMID 33176437, PMID 33176443, PMID 33185990, PMID 33826209, PMID 34081217, PMID 34218726, PMID 34643642, PMID 35236099, PMID 35325102, PMID 35852527, PMID 36061336, PMID 36503310, PMID 36597719, PMID 37641579, PMID 37680714, PMID 37831045, PMID 38032573, PMID 38215932, PMID 38493832, PMID 38739079, PMID 39056349, PMID 39217447, PMID 39217556, PMID 39217563, PMID 39217569, PMID 39230885, PMID 39352339, PMID 39477631, PMID 39513379, PMID 39909646, PMID 40126464, PMID 40200648, PMID 40285763, PMID 40503807
2023 (3), 2016 (2), 2018 (2), 1RC3NS070670-01 (1), 2005 (1), 2014 (1), 2019 (1)